重症监护病房患者连续血糖监测系统的准确性:范围综述
该范围综述系统检索PubMed和EMBASE(2023年12月5日至2024年5月21日),按PRISMA-ScR报告,共纳入96项评估ICU患者CGM准确性的研究。多数为观察性研究(91.7%)、成人患者(74%)、混合ICU(47.9%),80%评估皮下CGM,40.6%以动脉血样为参考。皮下CGM的MARD为6.6–30.5%,新型工厂校准CGM为9.7–20.6%;静脉CGM的MARD为5–14.2%,动脉内CGM为6.4–13%。作者结论认为CGM准确性报告异质性大,准确性因CGM和对照方法而异,血管内CGM可能更好,低血糖时可能更低。
要点
- 纳入96项ICU CGM准确性研究,91.7%为观察性研究,74%在成人患者中开展,47.9%在混合ICU。
- 皮下CGM的MARD范围为6.6–30.5%;新型工厂校准皮下CGM为9.7–20.6%。
- 静脉CGM的MARD为5–14.2%,动脉内CGM为6.4–13%,血管内CGM准确性可能更好。
- 仅56.3%的研究提及使用预设参考检测方案,40.6%以动脉血样为参考。
- 作者结论:CGM准确性报告异质性大,低血糖时准确性可能更低。
适用人群与场景
- ICU患者,多数研究为成人患者(74%),47.9%在混合ICU开展。
研究设计与关键结果
- 研究类型:范围综述,系统检索PubMed和EMBASE(2023年12月5日至2024年5月21日),按PRISMA-ScR报告,共识别2133项研究,纳入96项。
- 研究特征:91.7%为观察性研究,74%在成人患者中开展,47.9%在混合ICU,多数从2014年起,80%评估皮下CGM系统,40.6%以动脉血样为参考检测,56.3%提及使用预设参考检测方案。
- 准确性结果:所有皮下CGM研究的MARD范围为6.6–30.5%;新型工厂校准CGM的MARD范围为9.7–20.6%;静脉CGM的MARD为5–14.2%;动脉内CGM的MARD为6.4–13%。
证据类型、等级与局限
- 证据类型:范围综述(scoping review),遵循PRISMA-ScR指南报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为:ICU中CGM准确性报告异质性大,准确性因CGM和对照方法而异,血管内CGM可能更好,低血糖时准确性可能更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Glycemic control poses a challenge in intensive care unit (ICU) patients and dysglycemia is associated with poor outcomes. Continuous glucose monitoring (CGM) has been successfully implemented in the type 1 diabetes out-patient setting and renewed interest has been directed into the transition of CGM into the ICU. This scoping review aimed to provide an overview of CGM accuracy in ICU patients to inform future research and CGM implementation.
METHODS: We systematically searched PubMed and EMBASE between 5th of December 2023 and 21st of May 2024 and reported findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for scoping reviews (PRISMA-ScR). We assessed studies reporting the accuracy of CGM in the ICU and report study characteristics and accuracy outcomes.
RESULTS: We identified 2133 studies, of which 96 were included. Most studies were observational (91.7%), conducted in adult patients (74%), in mixed ICUs (47.9%), from 2014 and onward, and assessed subcutaneous CGM systems (80%) using arterial blood samples as reference test (40.6%). Half of the studies (56.3%) mention the use of a prespecified reference test protocol. The mean absolute relative difference (MARD) ranged from 6.6 to 30.5% for all subcutaneous CGM studies. For newer factory calibrated CGM, MARD ranged from 9.7 to 20.6%. MARD for intravenous CGM was 5-14.2% and 6.4-13% for intraarterial CGM.
CONCLUSIONS: In this scoping review of CGM accuracy in the ICU, we found great diversity in accuracy reporting. Accuracy varied depending on CGM and comparator, and may be better for intravascular CGM and potentially lower during hypoglycemia.
参考来源
- Nielsen CG, Grigonyte-Daraskeviciene M, Olsen MT, et al. Accuracy of continuous glucose monitoring systems in intensive care unit patients: a scoping review. Intensive Care Med. 2024. PMID: 39417874. doi:10.1007/s00134-024-07663-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。